Add to calendar

Join us for “Pathophysiology of Innate Anti-viral Responses after Corneal HSV-1 Infection to Suppress HSK” a keynote presentation by Dr. Amol Suryawanshi, School of Medicine – Ophthalmology, MizzouForward faculty candidate.  Dr. Suryawanshi will present on his research for approximately 40-minutes with a 20-minute question and answer session to follow.

Amol Suryawanshi is an Assistant Professor of Immunology in the Department of Pathobiology, College of Veterinary Medicine, Auburn University. Dr. Suryawanshi completed his Ph.D. with a research focus on Viral Immunopathology from the College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA. He received post-doctoral training in microbial pathogenesis, autoimmunity, and immuno-oncology at Tufts University School of Medicine and Cancer Immunotherapy Center, Augusta University. Following his post-doctoral training, Dr. Suryawanshi joined AbbVie Inc. as a Senior Scientist, where he worked on the development of Antibody Drug Conjugates (ADCs)-based novel immunotherapies for Inflammatory Bowel Disease (IBD), autoimmune, and neurodegenerative disease indications. In April 2018, Dr. Suryawanshi started his independent laboratory at the Department of Pathobiology, College of Veterinary Medicine, Auburn University. He serves as a reviewer and editorial board member for many international journals. He regularly serves on study section panels for NIA, NIAID, and NEI study section panels. He has coauthored >45 publications in peer-reviewed journals, >20 abstracts, and delivered several talks. His research focuses on understanding the role of innate and adaptive immunity, host-pathogen interaction, and molecular signaling mechanisms in immune cells during primary, latent, and recurrent herpes simplex virus 1 (HSV-1) infections. Dr. Suryawanshi is investigating how HSV-1 regulates macrophage immunometabolism to evade anti-viral immunity in a recently awarded R01 grant.

Dr. Suryawanshi’s research program’s long-term goals are: i) to understand and elucidate molecular and cellular events in cornea infiltrating immune cells that promote the selective induction of a robust anti-viral state with minimal activation of inflammatory responses during HSV-1-induced herpetic stromal keratitis (HSK) and (ii) use this knowledge to develop innovative, safer, and highly effective therapeutic strategies to treat HSK patients. His current and future research program involves 3 separate but interrelated projects studying the role of the innate immune system (neutrophils, macrophages, and DCs) during i) corneal HSV-1 infection, latency in the trigeminal ganglion (TG), reactivation, and recurrent infection, and ii) anti-tumor immunity. These are: 1) Role of the innate immune system during corneal HSV-1 infection, latency in the TG, and recurrent HSK.  and associated immunopathology, 2) Generation and characterization of novel nanobodies to suppress ocular inflammation and angiogenesis, and 3) A nanoparticle-based combinatorial approach to promote cancer cell immunogenic cell death (ICD) and enhance antigen-presenting cell’s immunogenicity. 

You can access Dr. Suryawanshi’s CV via OneDrive here:

​pdf icon Amol Suryawanshi_CV_January 2024.pdf (University log in required to access)

After the keynote, please provide candidate feedback with our brief survey.

0 people are interested in this event